Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia.

International journal of molecular sciences - 21 Feb 2022

Chi Sung-Gi, Minami Yosuke

Abstract excerpt

We describe recent updates of existing molecular-targeting agents and emerging novel gene-specific strategies. FLT3 and IDH inhibitors are being tested in combination with conventional chemotherapy for both medically fit patients and patients who are ineligible for intensive therapy. FLT3 inhibitors combined with non-cytotoxic agents, such as BCL-2 inhibitors, have potential therapeutic applicability. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Leukemia, Myeloid, Acute
Share to Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 35216478
DOI: 10.3390/ijms23042362
PMCID: PMC8879537

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia.PMID 35216478Read ↗

Updates on targeted therapies for acute myeloid leukaemia.Semantic proximity Read ↗

Emerging small molecular inhibitors as targeted therapies for high-risk acute myeloid leukemias.Semantic proximity Read ↗

Advances in the pharmacological management of acute myeloid leukemia in adults.Semantic proximity Read ↗

Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatmentsSemantic proximity Read ↗

Moving toward individualized target-based therapies in acute myeloid leukemia.Semantic proximity Read ↗

TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.Semantic proximity Read ↗

Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.Semantic proximity Read ↗

Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors.Semantic proximity Read ↗

Advancements in targeted therapies for acute myeloid leukemia.Semantic proximity Read ↗

Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia.Semantic proximity Read ↗

Molecular targeted therapy in acute myeloid leukemia.Semantic proximity Read ↗

<i>TP53</i> Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.